Evaluation of the KLOX BioPhotonic WoundGel System in the Treatment of Surgical Wounds

Surgical Wounds Clinical Trial

Official title:

A Prospective Randomized Clinical Study Evaluating the Safety and Efficacy of the KLOX BioPhotonic WoundGel System When Compared With Silicone Sheets in the Treatment of Surgical Wounds

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02604251
• Other study ID #: CL-K1002-P010
• Status: Completed
• Phase: N/A
• First received: November 6, 2015
• Last updated: March 5, 2018
• Start date: October 2015
• Est. completion date: November 2017

Study information

• Verified date: March 2018
• Source: KLOX Technologies Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, randomized, prospective, controlled study in patients having bilateral breast reduction. Objectives of the study are to evaluate the safety and efficacy of the KLOX BioPhotonic WoundGel System compared with the ones of Silicone Sheets in the treatment of surgical wounds.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: November 2017
• Est. primary completion date: April 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Signed and dated written informed consent form

2. Female patients, aged between 18 and 75 years old

3. Good general health, stable weight, free of systemic diseases such as diabetes, arthritis, HIV infection or genetic disorder that could influence the outcome of the treatment

4. Fitzpatrick skin type I to IV

5. Patients scheduled to go through bilateral breast reduction and expected to have newly formed post-surgery breast incisions of comparable length, located on comparable skin area

6. Patients able to understand, willing and able to comply with all study requirements

7. Patients must either be incapable of reproduction, or taking acceptable measures to prevent pregnancy and have a negative pregnancy test prior to participation in the Study

8. Females of childbearing potential must not be lactating at Study Screening and agree to use adequate contraceptive method during the Study

Exclusion Criteria:

1. Inability to understand the Study and its requirements or to give informed consent

2. Patient has participated in any other clinical study within 3 months prior to Study Screening and throughout the Study duration

3. Systemic antibiotic therapy or anti-inflammatory drugs or any other medication(s) that might interfere with healing within the last three months prior to Study Screening and throughout the Study duration

4. Current use of anticoagulants such as (but not limited to) warfarin, clopidogrel, enoxaparin or high doses of aspirin (> 162 mg daily)

5. Patient with current alcohol use or actively consuming drugs (addiction) as it may interfere with patient's ability to comply with Study procedures

6. Female patient pregnant, nursing or planning to become pregnant within the next 18 months

7. Patient is a current smoker or has been smoking or using nicotine product(s) in the last three months

8. Patient with known photosensitivity, taking drug(s) to treat photosensitivity, with concurrent disease (such as porphyria) or drug(s) (such as methotrexate or chloroquine) known to induce severe photosensitivity of the skin

9. Patients who are immunocompromised or taking immunosuppressive therapy

10. Any concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the Study investigational device

11. Patient has ongoing malignant disease of any type, active systemic, local skin infection or disease, autoimmune disease or any significant chronic disease which, in the opinion of the investigator, might interfere with the evaluation of the Study objectives or would result in non-compliance with the Study protocol

12. Patients with known hypersensitivity to pain medications

13. Patients with severe elastosis

14. Patients with severe or cystic acne on the area(s) to be treated

15. Presence of a metal stent or implant in the area(s) to be treated

16. Patients with derma resurfacing procedures or non-invasive skin-tightening procedures including medium/deep chemical peeling, microdermabrasion, laser therapy or prescription level glycolic acid treatment to the treatment area(s) within three months prior to Study Screening or during the Study

17. Patients anticipating the need for surgery or overnight hospitalization during the course of the Study

18. Patients with history of keloids or hypertrophic scars

19. Patients anticipating sun tanning bed or excessive sun exposure during the Study period

20. Patients with significant breast asymmetry that may result in asymmetrical operative incisions being made on the left and right breasts

21. Patients with breast asymmetry that may result in different post-operative tensions on the wounds of the left and right breasts

22. Patients having had surgery in the area to be incised within one year of Study Screening

23. Patients with tattoos in the areas of incisions

24. Patients with incisions that are actively bleeding

25. Patients with history of irradiated breast(s) in the area(s) to be treated.

Related Conditions & MeSH terms

• Surgical Wound
• Surgical Wounds
• Wounds and Injuries

Intervention

Device:
• KLOX BioPhotonic WoundGel System
Patients will then be re-randomized to one of the three comparisons: treatment starting on day 7 post-surgery, treatment starting on Day 21 post-surgery, or two consecutive treatments applied once weekly.
• Silicone sheets
Treatment of the surgical wounds with silicone sheets.

Locations

Country	Name	City	State
Canada	Victoria Park Medispa	Montreal	Quebec
Canada	Westmount Aesthetic Surgery Centre	Montreal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
KLOX Technologies Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Events, Serious Adverse Events and Device Incidents	Number of patients with adverse events, serious adverse events and device incidents	24 weeks
Secondary	Patient and Observer Scar Assessment Scale (POSAS)	Assessment of the efficacy of the KLOX BioPhotonic WoundGel System and of Silicone Sheets by the patient and by the investigator via the POSAS	up to 24 weeks
Secondary	Vancouver Scar Scale (VSS)	Assessment of the efficacy of the KLOX BioPhotonic WoundGel System and of Silicone Sheets by the investigator via the VSS	up to 24 weeks
Secondary	Efficacy as assessed by blinded experts panel	Assessment of the efficacy of the KLOX BioPhotonic WoundGel System and of Silicone Sheets by a blinded experts committee	up to 24 weeks
Secondary	Ease of wound management	Patient's self-assessment of ease of wound management by a specific questionnaire	up to 24 weeks